Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Fudan Forward S&T Co (600624.SS) as of Nov 2, 2026 is -43.42 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -117.25 M CNY — a change of -62.97% (higher).

EBITDA

-43.42 MCNY

YoY

-62.97%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Fudan Forward S&T Co is 2025 -43.42 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Fudan Forward S&T Co was 2024 -117.25 M CNY. It decreases by -62.97% higher compared to the previous year.

The Shanghai Fudan Forward S&T Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
76.54 M CNY
Jan 1, 2019
67.68 M CNY
Jan 1, 2020
-14.05 M CNY
Jan 1, 2021
-49.55 M CNY
Jan 1, 2022
20.10 M CNY
Jan 1, 2023
26.24 M CNY
Jan 1, 2024
-117.25 M CNY
Jan 1, 2025
-43.42 M CNY
The Shanghai Fudan Forward S&T Co EBITDA history
YEAREBITDAYoY
-43.42 MCNY-62.97%
-117.25 MCNY-546.86%
26.24 MCNY+30.53%
20.10 MCNY-140.57%
-49.55 MCNY+252.77%
-14.05 MCNY-120.76%
67.68 MCNY-11.57%
76.54 MCNY+13.60%
67.37 MCNY+13.22%
59.50 MCNY-1.30%
60.29 MCNY+29.09%
46.70 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Fudan Forward S&T Co is -43.42 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Fudan Forward S&T Co changed from -117.25 M CNY to -43.42 M CNY, representing a -62.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Shanghai Fudan Forward S&T Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Shanghai Fudan Forward S&T Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Shanghai Fudan Forward S&T Co